Biotechnology and Security

Advance U.S. leadership in biotechnology and biopharmaceutical innovation by strengthening the national bioinnovation ecosystem, reinforcing economic and national security, and shaping policies that enhance competitiveness amid intensifying global competition

The quantum industry is at an inflection point as the technology moves from academic to applied research. Quantum technology promises to unleash a wave of downstream innovation, carrying with it a range of opportunities and risks. While commercial quantum applications may be decades away, vigorous R&D enterprises and a supporting ecosystem of upstream suppliers are emerging to capitalize on the quantum revolution. RAI is exploring policies for growing and scaling a quantum industry in the United States to seize the quantum opportunity.

Contact Information

All Biotechnology and Security Content

Filter by

1 - 10 of 42 results

Rebuilding Resilience in U.S. Pharmaceutical Manufacturing

Tariffs and the recent executive orders aimed at expanding U.S. pharmaceutical manufacturing are insufficient on their own to address some of the key challenges facing U.S. manufacturers in regulation, permitting delays and talent development.

Commentary by Charles Wessner and Shruti Sharma — September 29, 2025

Audio Briefs

Rebuilding Resilience in U.S. Pharmaceutical Manufacturing

An audio version of “⁠Rebuilding Resilience in U.S. Pharmaceutical Manufacturing⁠,” a new commentary by CSIS’s Charles Wessner and Shruti Sharma. This audio was generated with text-to-speech by Eleven Labs. 

Podcast Episode by Charles Wessner and Shruti Sharma — September 29, 2025

Audio Briefs

If Private Sector R&D Is the Future, IP Policy Must Catch Up

In a future where the U.S. innovation ecosystem depends more heavily on private-sector investment across all stages of research, secure and predictable IP protections will be increasingly essential for sustaining long-term R&D investment.

Blog Post by Chris Borges — September 8, 2025